BioCryst Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
Revenue growth is driven by strong U.S. performance, expanding prescriber base, and high patient retention among super-responders. The pipeline is advancing with navenibart and a KLK5 inhibitor, while pediatric and community market penetration continues to rise.
-
Record ORLADEYO growth, European divestiture, and the Astria acquisition marked a transformative year, with profitability achieved and a strong cash position. ORLADEYO is on track for $1B peak sales by 2029, while pipeline assets like navenibart and BCX17725 drive future growth.
Fiscal Year 2025
-
Delivered record 2025 revenue and profitability, driven by ORLADEYO growth and strategic portfolio expansion. 2026 guidance projects continued double-digit revenue growth, with new pediatric and injectable HAE therapies advancing and strong U.S. market focus.
-
Management outlined strong ORLADEYO growth, with $1B peak sales targeted by 2029, and detailed the strategic rationale and expected synergies from the Astria acquisition. Nevenabart is positioned for a late-2028 launch, while pipeline updates and disciplined expense management support ongoing profitability.
-
Orladeyo delivered 37% year-over-year revenue growth and maintained high patient retention despite new competition. The company improved its financial position by selling its European business, repaying debt, and raising guidance, while advancing its pipeline and preparing for the Astria acquisition.
-
The acquisition brings a late-stage HAE therapy, Nevenibart, into the portfolio, supporting a rare disease growth strategy and leveraging existing commercial infrastructure. The deal is expected to be accretive, with minimal incremental costs, and positions the company for double-digit revenue growth through 2033.
-
Leadership transition and a European business sale are strengthening the balance sheet and enabling a focus on rare disease growth. ORLADEYO continues robust sales with strong patent protection, while pipeline programs in Netherton syndrome and DME are advancing. Strategic acquisitions are prioritized in a buyer-friendly market.
-
Record Q2 revenue and patient demand for ORLADEYO drove 45% year-over-year growth, with strong U.S. performance and expanding prescriber base. Sale of the European business will enable full debt repayment and further strengthen financials, supporting future pipeline and acquisition opportunities.
-
The sale of the European business for $250 million upfront and up to $14 million in milestones will enable debt repayment, $50 million in annual cost savings, and a focus on high-margin U.S. operations. The deal strengthens financials, accelerates pipeline development, and positions the company for future growth.
-
Strong commercial momentum and payer adoption for ORLADEYO are driving profitability ahead of schedule, with a robust pipeline targeting rare diseases and eye disorders. Financial discipline supports both debt reduction and future growth, positioning the company for significant market expansion.
-
ORLADEYO continues strong commercial growth, with raised revenue guidance and profitability expected this year. Two clinical programs—17725 for Netherton syndrome and Avoralstat for DME—are progressing, with key data updates anticipated by year-end.
-
Strong Q1 growth and high paid rates position ORLADEYO for robust U.S. and global sales targets. Pipeline advances in Netherton syndrome and DME offer potential for sustainable growth, with key clinical data expected by year-end.
-
Profitability and strong cash flow are driven by ORLADEYO’s commercial success and expanding reimbursement. Pipeline advances in Netherton syndrome and DME, plus a pediatric formulation, are set to deliver key data and regulatory milestones by year-end.
-
Q1 2025 saw record ORLADEYO revenue, a rapid rise in paid patient rates, and raised annual guidance to $580–$600 million. Full-year profitability is now expected in 2025, with strong demand, international expansion, and pipeline progress supporting long-term growth.
-
ORLADEYO continues its strong growth trajectory, with raised 2025 guidance and robust retention rates, supported by improved patient access and consistent messaging. The company expects to maintain significant market share despite new competition, while advancing two clinical pipeline programs and expanding globally.
-
Strong financial performance and profitability are expected, driven by ORLADEYO’s growth and robust real-world data. Two pipeline programs, including BCX17725 for Netherton syndrome and avoralstat for DME, are advancing with clinical data expected this year. Confidence remains high in maintaining market leadership despite new competitors.
-
Raised 2025 Orladeyo revenue guidance to $535–550M, driven by strong patient demand, improved paid drug rates, and robust real-world data. Pediatric NDA submission planned this year, and pipeline assets for Netherton syndrome and DME are advancing.
-
Revenue grew 34% in 2024, with strong U.S. and ex-U.S. demand and a path to $1B by 2029. Three major R&D milestones are expected in 2025, while robust financials and market research support durable growth and competitive positioning.
Fiscal Year 2024
-
Record 2024 performance with 34% ORLADEYO revenue growth, strong pipeline progress, and a $62.9M non-GAAP operating profit. 2025 guidance raised on robust demand and Medicare improvements, with positive cash flow and $1B global revenue targeted by 2029.
-
ORLADEYO continues strong growth as the only oral HAE prophylactic, with robust data supporting efficacy, high adherence, and expanding prescriber base. Pipeline advances include a pediatric oral formulation, a KLK5 inhibitor for Netherton syndrome, and Avoralstat for DME, with key data expected in 2025.
-
ORLADEYO continues to deliver strong growth, targeting $1 billion in revenue by 2029, with robust patient retention and a sticky market dynamic. Pipeline programs for Netherton syndrome and diabetic macular edema are advancing, while financials are improving with rising paid drug rates and a path to profitability.
-
Strong demand and improved paid therapy rates have driven revenue guidance higher, with profitability expected soon. Orladeyo’s market leadership is reinforced by high retention and payer progress, while pipeline assets for Netherton syndrome and DME are advancing with key data expected in 2025.
-
ORLADEYO revenue grew 36% year-over-year, driving strong operating profit and cash flow, with 2024 guidance raised to $430–$435 million. Pipeline advances include BCX17725 for Netherton syndrome and avoralstat for DME, both entering patient studies in 2025.
-
Orladeyo continues to drive strong revenue growth and market adoption, with increasing physician confidence and expansion into pediatric and ex-US markets. The pipeline is advancing with programs for Netherton syndrome and DME, and profitability is expected soon.
-
ORLADEYO continues to drive strong patient and revenue growth, with robust U.S. and international expansion and a clear path to $1 billion in peak sales. Pipeline progress includes two new clinical programs, and financials show operating profitability with declining royalty obligations.
-
ORLADEYO continues robust growth, driven by patient preference for oral therapy and strong efficacy, with global sales expected to reach $1 billion by 2029. Pediatric expansion, new pipeline programs for rare diseases, and international launches support long-term growth.
-
ORLADEYO achieved record Q2 revenue, driving a 34% year-over-year increase and prompting a $30–$35 million upward revision in 2024 guidance. Operational improvements boosted paid patient rates and compliance, while pipeline progress and market expansion support a clear path to $1 billion peak revenue.
-
ORLADEYO's strong Q1 2024 growth is driven by robust patient demand and increasing paid patient rates, with 2024 sales expected to reach $390–$400 million. Profitability is on track for 2024–2026, while pipeline programs in PNH, Netherton syndrome, and DME advance toward key milestones.